Abstract:Inhibition of histone deacetylase (HDAC) results in growth arrest, differentiation, and apoptosis in nearly all tumor cell lines, promoting HDACs as promising targets for antitumor therapy. In our previous study We developed a novel series of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as HDAC inhibitors (HDACi), among which compound 7d exhibited promising HDAC8 inhibitory and antiproliferative activities. Herein, we report the design and development of a new class of tetrahydroisoquinoline-bearing hydroxamic acid analogues as potential HDACi and anticancer agents. In vitro biological evaluation of these compounds showed improved HDAC8 inhibition (compounds 31a and 31b exhibited mid-nM IC50 values against HDAC8) and potent growth inhibition in multiple tumor cell lines. Most importantly, compounds 25e, 34a, and 34b exhibited excellent in vivo anticancer activities in a human breast carcinoma (MDA-MB-231) xenograft model compared with suberoylanilide hydroxamic acid (SAHA), an approved HDACi. Collectively, our results indicate that tetrahydroisoquinoline bearing a hydroxamic acid is an excellent template to develop novel HDACi as potential anticancer agents.

Design, synthesis and preliminary bioactivity studies of 1,2-dihydrobenzo[d]isothiazol-3-one-1,1-dioxide hydroxamic acid derivatives as novel histone deacetylase inhibitors.

Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.

Design, synthesis, and preliminary bioactivity evaluation of N-benzylpyrimidin-2-amine derivatives as novel histone deacetylase inhibitor.

Design, Synthesis and Biological Evaluation of Saccharin-Based N -Hydroxybenzamides As Histone Deacetylases (hdacs) Inhibitors

Design, Synthesis, and Preliminary Bioactivity Studies of Substituted Purine Hydroxamic Acid Derivatives As Novel Histone Deacetylase (HDAC) Inhibitors

N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity.

Design, Synthesis and Preliminary Bioactivity Evaluations of Substituted Quinoline Hydroxamic Acid Derivatives As Novel Histone Deacetylase (hdac) Inhibitors

Design and Synthesis of a New Generation of Substituted Purine Hydroxamate Analogs As Histone Deacetylase Inhibitors

Design, Synthesis and Biological Evaluation of Tyrosine-Based Hydroxamic Acid Analogs As Novel Histone Deacetylases (hdacs) Inhibitors.

Design, synthesis and bioevaluation of novel N-heterocyclic hydroxamic acids as histone deacetylase inhibitors and their antitumor activity study

Design, Synthesis and Preliminary Activity Assay of 1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acid Derivatives As Novel Histone Deacetylases (hdacs) Inhibitors.

Design, Synthesis and Biological Evaluation of Isoquinoline-Based Derivatives As Novel Histone Deacetylase Inhibitors

Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.

Development of Hydroxamate-Based Histone Deacetylase Inhibitors Containing 1,2,4-Oxadiazole Moiety Core with Antitumor Activities.

Design, Synthesis and Biological Evaluation of 4-Anilinothieno[2,3-d]pyrimidine-based Hydroxamic Acid Derivatives As Novel Histone Deacetylase Inhibitors.

Design, Synthesis, and Antitumor Evaluation of Histone Deacetylase Inhibitors with L-Phenylglycine Scaffold

Design, Synthesis, and Preliminary Bioactivity Evaluation of N1‐hydroxyterephthalamide Derivatives with Indole Cap As Novel Histone Deacetylase Inhibitors

Syntheses and Biological Evaluation of Novel Hydroxamic Acid Derivatives Containing Purine Moiety As Histone Deacetylase Inhibitors

Design, Synthesis, and Biological Evaluation of 1, 3-Disubstituted-pyrazole Derivatives As New Class I and IIb Histone Deacetylase Inhibitors

Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups

A hybrid of thiazolidinone with the hydroxamate scaffold for developing novel histone deacetylase inhibitors with antitumor activities